Edible vaccines mark a groundbreaking approach to immunization by harnessing plant-based resources for vaccine development. Unlike conventional injections, these vaccines are ingested through genetically modified plants. This innovative strategy aims to improve accessibility, lower costs, and streamline vaccine distribution, particularly in regions with limited resources. The edible vaccine process involves introducing a specific gene into the plant's genetic code, enabling it to produce a vaccine protein. The potential of administering vaccines orally eliminates the necessity for injections, offering a more convenient and less invasive method of immunization. Edible vaccines present notable advantages, including heightened stability, simplified transportation, and reduced reliance on cold storage. Moreover, they hold the potential to overcome challenges associated with needle-based vaccination, fostering greater acceptance and participation in immunization initiatives. Ongoing research and development in this field may herald a transformative shift in global vaccination strategies, addressing health disparities and promoting extensive immunization coverage.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey